Clinical Trials

FDA Approves J&J Combination for Early Myeloma Relapse
Management & Regulatory FDA Approves J&J Combination for Early Myeloma Relapse

Ivan Kairatov is at the forefront of biopharmaceutical innovation, specializing in how next-generation therapies reshape the landscape of oncology. With a robust background in research and development, he has monitored the evolution of multiple myeloma treatments from traditional chemotherapies to

Can saRNA Injections Prevent Heart Failure After a Heart Attack?
Tech & Innovation Can saRNA Injections Prevent Heart Failure After a Heart Attack?

The sudden occlusion of a coronary artery initiates a catastrophic sequence of cellular death that fundamentally alters the architectural integrity of the human heart within minutes. While contemporary emergency medicine has become remarkably efficient at reestablishing blood flow through

Glioblastoma DNA Immunotherapy – Review
Biotech & Bioprocessing Glioblastoma DNA Immunotherapy – Review

The therapeutic landscape for patients with glioblastoma has remained largely unchanged for decades, characterized by a persistent and frustrating survival ceiling that rarely extends beyond fifteen months for those with the most aggressive tumor markers. This lack of progress stems from the unique

CAR-Astrocyte Cellular Immunotherapy – Review
Research & Development CAR-Astrocyte Cellular Immunotherapy – Review

The human brain possesses an intricate waste-clearance system that, when functioning correctly, prevents the toxic buildup of proteins associated with cognitive decline. However, for millions of individuals, this biological janitorial service fails, leading to the relentless progression of

Roche and Zealand Obesity Drug Fails to Impress Investors
Research & Development Roche and Zealand Obesity Drug Fails to Impress Investors

The pharmaceutical industry is currently witnessing a gold rush of unprecedented proportions as global giants race to claim dominance in the multi-billion-dollar obesity treatment sector. This week, the spotlight turned toward the highly anticipated Phase 2 results of petrelintide, a drug developed

Can J&J’s New Approval Redefine Multiple Myeloma Care?
Research & Development Can J&J’s New Approval Redefine Multiple Myeloma Care?

The sudden transformation of multiple myeloma from a terminal diagnosis to a manageable chronic condition reached a pivotal junction with the Food and Drug Administration's recent decision to grant full approval to a high-impact combination therapy. By pairing the bispecific antibody Tecvayli with

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later